These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 7683356

  • 1. In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients.
    Gattei V, Aldinucci D, Petti MC, Da Ponte A, Zagonel V, Pinto A.
    Leukemia; 1993 May; 7 Suppl 1():42-8. PubMed ID: 7683356
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of the blast self-renewal capacity in patients with acute myeloid leukemia.
    Nara N, Kurokawa H, Tanikawa S, Tomiyama J, Nagata K.
    Cancer; 1994 Jan 01; 73(1):92-7. PubMed ID: 8275443
    [Abstract] [Full Text] [Related]

  • 3. A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
    Yang GS, McCulloch EA.
    Hematol Pathol; 1992 Jan 01; 6(3):125-30. PubMed ID: 1385380
    [Abstract] [Full Text] [Related]

  • 4. Effects of recombinant human tumor necrosis factor on the self-renewal capacity of leukemia blast progenitors in acute myeloblastic leukemia.
    Nagata K, Tohda S, Suzuki T, Nara N.
    Leukemia; 1989 Sep 01; 3(9):626-30. PubMed ID: 2761317
    [Abstract] [Full Text] [Related]

  • 5. Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.
    Petti MC, Mandelli F, Zagonel V, De Gregoris C, Merola MC, Latagliata R, Gattei V, Fazi P, Monfardini S, Pinto A.
    Leukemia; 1993 May 01; 7 Suppl 1():36-41. PubMed ID: 7683355
    [Abstract] [Full Text] [Related]

  • 6. Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
    Ryningen A, Stapnes C, Bruserud Ø.
    Leuk Res; 2007 Sep 01; 31(9):1303-13. PubMed ID: 17416413
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxicity of 4-hydroperoxycyclophosphamide for the blast progenitors of acute myeloblastic leukemia.
    Nara N, Suzuki T, Yamashita Y, Murohashi I, Aoki N.
    Cancer Res; 1988 May 01; 48(9):2348-52. PubMed ID: 3162711
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3',5'-cyclic monophosphate.
    Pinto A, Aldinucci D, Gattei V, Zagonel V, Tortora G, Budillon A, Cho-Chung YS.
    Proc Natl Acad Sci U S A; 1992 Oct 01; 89(19):8884-8. PubMed ID: 1329084
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the in vitro growth of blast progenitors from acute myeloblastic leukemia patients by transforming growth factor-beta (TGF-beta).
    Nara N, Tohda S, Nagata K, Suzuki T, Yamashita Y.
    Leukemia; 1989 Aug 01; 3(8):572-7. PubMed ID: 2473359
    [Abstract] [Full Text] [Related]

  • 10. The in vitro growth patterns and drug sensitivities of leukemic blast progenitors among the subtypes of acute myelocytic leukemia.
    Nara N, Chen GJ, Murohashi I, Tohda S, Imai Y, Tomiyama J, Nagata K, Suzuki T, Tanikawa S, Shiina S.
    Exp Hematol; 1992 Aug 01; 20(7):904-8. PubMed ID: 1628709
    [Abstract] [Full Text] [Related]

  • 11. The role of decitabine for the treatment of acute myeloid leukemia.
    Ganetsky A.
    Ann Pharmacother; 2012 Nov 01; 46(11):1511-7. PubMed ID: 23115225
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sensitivity of hematopoietic progenitors of acute myeloblastic leukemia to new compounds derived from marine organisms.
    Lishner M, Shur I, Bleiberg I, Rudi A, Kashman Y, Fabian I.
    Leukemia; 1995 Sep 01; 9(9):1543-8. PubMed ID: 7658723
    [Abstract] [Full Text] [Related]

  • 14. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
    Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, De Angelis V, Monfardini S, Pinto A.
    Leukemia; 1993 May 01; 7 Suppl 1():30-5. PubMed ID: 7683354
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
    Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU.
    Exp Hematol; 1992 Jun 01; 20(5):558-64. PubMed ID: 1587302
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of recombinant human M-CSF on the proliferation of leukemic blast progenitors in AML patients.
    Suzuki T, Nagata K, Murohashi I, Nara N.
    Leukemia; 1988 Jun 01; 2(6):358-62. PubMed ID: 3287022
    [Abstract] [Full Text] [Related]

  • 20. Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
    Momparler RL, Côté S, Momparler LF.
    Leuk Res; 2013 Aug 01; 37(8):980-4. PubMed ID: 23660386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.